|
1
|
Khan SA, Davidson BR, Goldin RD, Heaton N,
Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD,
Thillainayagam AV, et al: Guidelines for the diagnosis and
treatment of cholangiocarcinoma: An update. Gut. 61:1657–1669.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bridgewater J, Galle PR, Khan SA, Llovet
JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the
diagnosis and management of intrahepatic cholangiocarcinoma. J
Hepatol. 60:1268–1289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and
treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bragazzi MC, Carpino G, Venere R, Semeraro
R, Gentile R, Gaudio E and Alvaro D: Cholangiocarcinoma:
Epidemiology and risk factors. Transl Gastrointest Cancer. 1:21–32.
2012.
|
|
5
|
Shaib YH, Davila JA, Henderson L, McGlynn
KA and El-Serag HB: Endoscopic and surgical therapy for
intrahepatic cholangiocarcinoma in the United States: A
population-based study. J Clin Gastroenterol. 41:911–917. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng CT, Chu YY, Yeh CN, Huang SC, Chen
MH, Wang SY, Tsai CY, Chiang KC, Chen YY, Ma MC, et al: Peritumoral
SPARC expression and patient outcome with resectable intrahepatic
cholangiocarcinoma. Onco Targets Ther. 8:1899–1907. 2015.PubMed/NCBI
|
|
7
|
Shirai K, Ebata T, Oda K, Nishio H,
Nagasaka T, Nimura Y and Nagino M: Perineural invasion is a
prognostic factor in intrahepatic cholangiocarcinoma. World J Surg.
32:2395–2402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen TC, Jan YY and Yeh TS: K-ras mutation
is strongly associated with perineural invasion and represents an
independent prognostic factor of intrahepatic cholangiocarcinoma
after hepatectomy. Ann Surg Oncol. 19 Suppl 3:S675–S681. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nathan H, Aloia TA, Vauthey JN, Abdalla
EK, Zhu AX, Schulick RD, Choti MA and Pawlik TM: A Proposed staging
system for intrahepatic cholangiocarcinoma. Ann Surg Oncol.
16:14–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okabayashi T, Yamamoto J, Kosuge T,
Shimada K, Yamasaki S, Takayama T and Makuuchi M: A new staging
system for mass-forming intrahepatic cholangiocarcinoma: Analysis
of preoperative and postoperative variables. Cancer. 92:2374–2383.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chaiteerakij R, Harmsen WS, Marrero CR,
Aboelsoud MM, Ndzengue A, Kaiya J, Therneau TM, Sanchez W, Gores GJ
and Roberts LR: A new clinically based staging system for perihilar
cholangiocarcinoma. Am J Gastroenterol. 109:1881–1890. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paul A, Kaiser GM, Molmenti EP, Schroeder
T, Vernadakis S, Oezcelik A, Baba HA, Cicinnati VR and Sotiropoulos
GC: Klatskin tumors and the accuracy of the Bismuth-Corlette
classification. Am Surg. 77:1695–1699. 2011.PubMed/NCBI
|
|
13
|
Matsuo K, Rocha FG, Ito K, D'Angelica MI,
Allen PJ, Fong Y, Dematteo RP, Gonen M, Endo I and Jarnagin WR: The
Blumgart preoperative staging system for hilar cholangiocarcinoma:
Analysis of resectability and outcomes in 380 patients. J Am Coll
Surg. 215:343–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zervos EE, Osborne D, Goldin SB,
Villadolid DV, Thometz DP, Durkin A, Carey LC and Rosemurgy AS:
Stage does not predict survival after resection of hilar
cholangiocarcinomas promoting an aggressive operative approach. Am
J Surg. 190:810–815. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liang KH, Lin CC and Yeh CT: GALNT14 SNP
as a potential predictor of response to combination chemotherapy
using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Pharmacogenomics. 12:1061–1073. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin WR, Hsu CW, Chen YC, Chang ML, Liang
KH, Huang YH and Yeh CT: GALNT14 genotype, α-fetoprotein and
therapeutic side effects predict post-chemotherapy survival in
patients with advanced hepatocellular carcinoma. Mol Clin Oncol.
2:630–640. 2014.PubMed/NCBI
|
|
17
|
Yeh CT, Liang KH, Lin CC, Chang ML, Hsu CL
and Hung CF: A single nucleotide polymorphism on the GALNT14 gene
as an effective predictor of response to chemotherapy in advanced
hepatocellular carcinoma. Int J Cancer. 134:1214–1224. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang KH, Lin CL, Chen SF, Chiu CW, Yang
PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, et al: GALNT14
genotype effectively predicts the therapeutic response in
unresectable hepatocellular carcinoma treated with transcatheter
arterial chemoembolization. Pharmacogenomics. 17:353–366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wagner KW, Punnoose EA, Januario T,
Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF,
Totpal K, et al: Death-receptor O-glycosylation controls tumor-cell
sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med.
13:1070–1077. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Mariano M, Gallesio R, Chierici M,
Furlanello C, Conte M, Garaventa A, Croce M, Ferrini S, Tonini GP
and Longo L: Identification of GALNT14 as a novel neuroblastoma
predisposition gene. Oncotarget. 6:26335–26346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shamseldin HE, Tulbah M, Kurdi W, Nemer M,
Alsahan N, Al Mardawi E, Khalifa O, Hashem A, Kurdi A, Babay Z, et
al: Identification of embryonic lethal genes in humans by
autozygosity mapping and exome sequencing in consanguineous
families. Genome Biol. 16:1162015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ihle MA, Fassunke J, König K, Grünewald I,
Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Büttner R and
Merkelbach-Bruse S: Comparison of high resolution melting analysis,
pyrosequencing, next generation sequencing and immunohistochemistry
to conventional Sanger sequencing for the detection of p.V600E and
non-p.V600E BRAF mutations. BMC Cancer Cancer Cancer. 14:132014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang KH, Yang PC and Yeh CT: Genotyping
the GALNT14 gene by joint analysis of two linked single nucleotide
polymorphisms using liver tissues for clinical and geographical
comparisons. Oncol Lett. 8:2215–2220. 2014.PubMed/NCBI
|
|
24
|
Inokawa Y, Inaoka K, Sonohara F, Hayashi
M, Kanda M and Nomoto S: Molecular alterations in the
carcinogenesis and progression of hepatocellular carcinoma: Tumor
factors and background liver factors. Oncol Lett. 12:3662–3668.
2016.PubMed/NCBI
|
|
25
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, surveillance, and diagnosis. Semin Liver Dis.
30:3–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yeh CT, Huang YH, Liang KH, Chang ML, Hsu
CW, Chen YC, Chen TC, Yeh TS and Lee WC: Segregation of signaling
proteins as prognostic predictors for local recurrence and distant
metastasis in hepatocellular carcinoma. Int J Oncol. 44:491–504.
2014.PubMed/NCBI
|
